Scholar IQ
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
On this page:OverviewPublicationsResearchersInstitutionsOpen access
ScholarIQanswers from OpenAlex

Edinburgh Cancer Research

InstitutionResearch output, impact & collaborations

Edinburgh Cancer Research is a research organisation in Edinburgh, GB. OpenAlex records 6,063 works and 695,904 citations for it. 1,270 researchers list it as their most recent affiliation.

6,063
Works
695,904
Citations
1,270
Researchers
87.3
Avg h-index

How has Edinburgh Cancer Research's publication output changed over time?

ScholarIQpublication output · 2004–2023

Output grew0% over the shown period — from 1 works in 2004 to 1 in 2023.

1
1
1
1
1
1
1
3
1
1
2004200520112012201420162018201920222023

Who are the most-cited researchers behind Edinburgh Cancer Research?

ScholarIQtop researchers by citations
1
Helen M. Colhoun · Diabetes Treatment and Management
512 works40,787 citations

What are the most-cited papers on Edinburgh Cancer Research?

ScholarIQmost cited works
Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
Martine Piccart, Marion Procter, Brian Leyland‐Jones, Aron Goldhirsch, Michael Untch, Ian Smith, Luca Gianni, José Baselga, Richard H. Bell, Christian Jackisch, David Cameron, Mitch Dowsett, Carlos H. Barrios, Günther Steger, Chiun‐Sheng Huang, Michael Andersson, Moshe Inbar, Mikhail Lichinitser, István Láng, Ulrike Nitz, Hiroji Iwata, Christoph Thomssen, Caroline Lohrisch, Thomas Suter, Josef Rüschoff, Tamás Sütö, Victoria Greatorex, Carol Ward, Carolyn Straehle, Eleanor McFadden, Mirko Dolci, Richard D. Gelber
New England Journal of Medicine. 20055,111 CitationsOPEN ACCESS
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
Patricia Cortazar, Lijun Zhang, Michael Untch, Keyur Mehta, Joseph P. Costantino, Norman Wolmark, Hervé Bonnefoi, David Cameron, Luca Gianni, Pinuccia Valagussa, Sandra M. Swain, Tatiana M. Prowell, Sibylle Loibl, D. Lawrence Wickerham, Jan Bogaerts, José Baselga, Charles M. Perou, Gideon M. Blumenthal, Jens‐Uwe Blohmer, Eleftherios P. Mamounas, Jonas Bergh, Semiglazov Vf, Robert Justice, Holger Eidtmann, Soonmyung Paik, Martine Piccart, Rajeshwari Sridhara, Peter A. Fasching, Leen Slaets, Shenghui Tang, Bernd Gerber, Charles E. Geyer, Richard Pazdur, Nina Ditsch, Priya Rastogi, W. Eiermann, Gϋnter von Minckwitz
The Lancet. 20144,765 CitationsOPEN ACCESS
Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial
Helen M. Colhoun, D. J. Betteridge, Paul N. Durrington, G. A. Hitman, H. A. W. Neil, Shona Livingstone, Margaret J. Thomason, Michael I. Mackness, Valentine Charlton-Menys, John Fuller
The Lancet. 20043,793 Citations
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais, Rafael Díaz, Mark Lakshmanan, Prem Pais, Jeffrey L. Probstfield, Jeffrey S. Riesmeyer, Matthew C. Riddle, Lars Rydén, Denis Xavier, Charles Atisso, Leanne Dyal, Stephanie Hall, Rao Ps, G.C. Wong, Álvaro Avezum, Jan Basile, Namsik Chung, Ignacio Conget, William C. Cushman, Edward Franek, Nicolae Hâncu, M Hanefeld, Shaun Holt, Petr Janský, Mátyás Keltai, Fernando Laņas, Lawrence A. Leiter, Patricio López‐Jaramillo, Ernesto Muñoz, Valdis Pīrāgs, Nana Pogosova, Peter Raubenheimer, Jonathan E. Shaw, Wayne Huey‐Herng Sheu, Theodora Temelkova‐Kurktschiev, Mercedes Abella, Andrea Alebuena, Sandra Almagro, Eduardo Amoroso, Paula Anadon, Elizabeth Andreu, Guillermo Aristimuño, Maria Arzadun, María Antonietta Barbieri, Raúl Barcudi, Ines Bartolacci, Gabriel Bolobanich, Anselmo P. Bordonava, Miguel Bustamante Labarta, B. Bustos, Alberto Caccavo, Alejandra Camino, María del Rocío Cantero, Maria Carignano, Luis R Cartasegna, Marcela Cipullo, Víctor Commendatore, Victoria Conosciuto, Osvaldo Costamagna, Claudia A. Crespo, Jose Cuello, Carlos Alberto Cuneo, Sandra Cusimano, Sofia Dean, Claudio Fabián Dituro, Andrea Domínguez, Miguel Farah, Alberto Fernandez, Florencia Fernandez, Adriana Cristina Ferrari, Patricia Flammia, José Antonio Fuentealba, Karina Beatriz Gallardo, C. Perez Garcia, Ruben Garcia Duran, Marcelo Garrido, Rodolfo Gavícola, Claudio Gerbaudo, Graciela Gilli, Ana Paula Giotto, Pedro Godoy Bolzán, Oscar Gómez Vilamajó, Fernando Guerlloy, Cristian Guridi, Narcisa Gutierrez Garrido, Eduardo Hasbani, Sonia Hermida, Miguel Hominal, Adrian D. Hrabar, Adrián Ingaramo, Alejandra Izzicupo, Mario Krynski, Mariana Lagrutta, Paulina Virginia Lanchiotti, Maria Langhe, Veronica Leonard, Javier Llanos, Ricardo López Santi
The Lancet. 20193,109 CitationsOPEN ACCESS
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Kathleen N. Moore, Nicoletta Colombo, Giovanni Scambia, Byoung‐Gie Kim, Ana Oaknin, Michael Friedländer, Alla Lisyanskaya, Anne Floquet, Alexandra Léary, Gabe S. Sonke, Charlie Gourley, Susana Banerjee, Amit M. Oza, Antonio González-Martı́n, Carol Aghajanian, William H. Bradley, Cara Mathews, Joyce F. Liu, Elizabeth Lowe, Ralph Bloomfield, Paul DiSilvestro
New England Journal of Medicine. 20182,881 CitationsOPEN ACCESS

How much of the research on Edinburgh Cancer Research is open access?

ScholarIQopen access share
83%OPEN ACCESS
Gold
0%
Green
42%
Hybrid
0%
Bronze
42%
Closed
17%

Related on ScholarIQ

Breast Cancer Treatment Studies
Top Topic
Epigenetics and DNA Methylation
Top Topic
Genetic Associations and Epidemiology
Top Topic
Cancer Genomics and Diagnostics
Top Topic
Ovarian cancer diagnosis and treatment
Top Topic
HER2/EGFR in Cancer Research
Top Topic
470M+ articles · free account